John Lapré adds: "The most striking advantage of the ImagingRing is the spacious 121 cm bore diameter. The wide bore enables patient imaging in the lithotomy ("knees up") position for the majority of brachytherapy cases - gynecological and prostate cancer patients."
The ImagingRing product line was developed by medPhoton GmbH (Salzburg, Austria). Elekta has exclusive distribution rights for the mobile ImagingRing in brachytherapy. "On behalf of all at medPhoton, I'm very happy with the collaboration with Elekta," says Heinz Deutschmann, CEO of medPhoton. "Many of us have a background in radiation oncology, where we've developed technology for adaptive image-guided solutions for years. It's good to see that we're closing the loop now, with the mobile ImagingRing coming to robotically assisted, image-guided brachytherapy."
*Elekta Studio is comprised of multiple medical devices, some of which may not yet be available in all markets. Confirm availability with your local Elekta representative.
About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange.
SOURCE Elekta
Back to HCB News
